Tourette's Syndrome

1. Overview

Tourette's Syndrome (TS) is a childhood-onset neurodevelopmental disorder characterised by the presence of multiple motor tics and at least one vocal (phonic) tic, persisting for more than one year. Named after French neurologist Georges Gilles de la Tourette who first described the condition in 1885, TS represents the most severe form of chronic tic disorders and exists on a spectrum of tic disorders. [1,2]

Tics are sudden, rapid, recurrent, non-rhythmic motor movements or vocalisations that are experienced as irresistible but can be suppressed temporarily. The hallmark feature distinguishing tics from other involuntary movements is the premonitory urge—an uncomfortable sensation that precedes the tic and is temporarily relieved by its execution. The condition typically follows a characteristic waxing and waning course, with tic severity fluctuating over time and different tics replacing one another. [3]

Tourette's Syndrome is much more than a tic disorder. It is commonly associated with psychiatric comorbidities, particularly Attention-Deficit/Hyperactivity Disorder (ADHD) and Obsessive-Compulsive Disorder (OCD), often referred to as the "Tourette's triad." In many cases, these comorbidities cause greater functional impairment than the tics themselves and are critical targets for intervention. While Tourette's is often portrayed in media as involving involuntary swearing (coprolalia), this symptom occurs in fewer than 10% of patients and is not required for diagnosis. [4,5]

Understanding Tourette's Syndrome is essential for paediatricians, neurologists, psychiatrists, and general practitioners, as timely diagnosis, psychoeducation, and appropriate management can significantly improve quality of life and long-term outcomes.

---

2. Epidemiology

Demographics

Prevalence
Tourette's Syndrome affects approximately 0.3-1% of school-aged children, with higher rates when milder tic disorders are included. Population-based studies suggest that tic disorders as a whole may affect up to 1-5% of children. [6,7]

Gender
Males are affected 3-4 times more frequently than females. The reason for this sex difference is not fully understood but may relate to hormonal, genetic, or neurodevelopmental factors. [8]

Age of Onset
Tics typically begin between ages 4-6 years, with the average age of diagnosis around 7 years. Motor tics usually appear first, followed by vocal tics. Peak tic severity occurs in early adolescence (ages 10-12 years), with subsequent improvement in late adolescence and young adulthood in most cases. [9]

Ethnicity and Geography
Tourette's Syndrome occurs across all ethnic groups and geographic regions. However, prevalence estimates vary depending on ascertainment methods and diagnostic criteria used.

Risk Factors

Comorbidities

Psychiatric comorbidities are the rule rather than the exception in Tourette's Syndrome: [4,5]

• ADHD: 50-60% of patients
• Obsessive-Compulsive Disorder (OCD): 30-50% of patients
• Anxiety disorders: 30-40% of patients
• Depression: 20-30% of patients
• Autism Spectrum Disorder: 5-10% overlap
• Sleep disorders: Common, including insomnia and sleep-related movements
• Learning difficulties: Up to 30% have specific learning disabilities

Clinical Pearl: In many patients, especially adolescents and adults, the comorbid ADHD or OCD causes greater functional impairment than the tics themselves. Failure to recognise and treat these comorbidities is a common clinical error.

---

3. Aetiology and Pathophysiology

Genetics

Tourette's Syndrome is highly heritable, with genetic factors accounting for approximately 50-77% of the variance in tic severity. Twin studies show concordance rates of 50-70% in monozygotic twins versus 10-20% in dizygotic twins. [10]

However, the genetic architecture is complex and polygenic. No single "Tourette gene" exists. Genome-wide association studies (GWAS) have identified multiple risk loci, including genes involved in:

• Dopaminergic neurotransmission (e.g., dopamine receptor genes)
• GABAergic signalling
• Glutamatergic pathways
• Neurodevelopment and synaptic plasticity

Rare variants in genes such as SLITRK1, HDC (histidine decarboxylase), and CNTNAP2 have been reported in small subsets of patients, but these account for only a minority of cases. [13]

Neurobiological Mechanisms

Exam Detail: Cortico-Striato-Thalamo-Cortical (CSTC) Circuits
Tourette's Syndrome is fundamentally a disorder of the basal ganglia circuits that regulate motor control and habit formation. The prevailing model involves dysfunction in the CSTC loops:

1. Striatum (Caudate and Putamen): The striatum normally acts as a "gatekeeper," inhibiting unwanted motor programmes. In TS, there is reduced tonic inhibition, leading to the release of inappropriate motor and vocal patterns.

2. Globus Pallidus and Thalamus: Dysregulation in the direct and indirect pathways of the basal ganglia leads to disinhibition of thalamo-cortical projections.

3. Motor and Premotor Cortex: Abnormal activity in cortical areas generates the tics. Premonitory urges may arise from altered sensorimotor integration in the insula and supplementary motor area (SMA).

Dopamine Hypothesis
Evidence supports dopaminergic hyperactivity in the striatum:

• Dopamine antagonists (antipsychotics) reduce tic severity.
• Dopamine agonists (e.g., stimulants) can exacerbate tics in some individuals.
• Post-mortem studies show increased dopamine transporter density.
• PET studies demonstrate increased striatal dopamine release. [14]

However, dopamine is not the only neurotransmitter involved. Abnormalities in GABA, glutamate, serotonin, and histamine systems have also been implicated. [15]

Neuroimaging Findings

• Structural MRI: Reduced volumes in caudate nucleus, putamen, and globus pallidus; thinner sensorimotor cortices.
• Functional MRI: Abnormal activation in basal ganglia, SMA, and prefrontal cortex during tic suppression.
• Diffusion Tensor Imaging (DTI): Altered white matter microstructure in cortico-striatal pathways. [16]

Environmental and Immunological Factors

PANDAS and PANS
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections (PANDAS) is a controversial entity proposing that a subset of tic and OCD cases result from autoimmune responses to Group A Streptococcus. The broader term PANS (Pediatric Acute-onset Neuropsychiatric Syndrome) includes non-streptococcal triggers. [12]

Criteria for PANDAS include:

• Abrupt, dramatic onset of OCD or severely restricted food intake
• Presence of neuropsychiatric symptoms (anxiety, tics, behavioural regression)
• Temporal association with Group A Strep infection
• Association with neurological abnormalities (choreiform movements, motor hyperactivity)

While some patients clearly experience post-infectious exacerbations, the evidence for a distinct autoimmune subtype remains debated. Testing for anti-streptolysin O (ASOT) titres is reasonable in cases of explosive onset, but routine testing in all TS patients is not recommended.

Perinatal Factors
Maternal smoking, prenatal stress, low birth weight, and obstetric complications have been associated with modestly increased risk for tic disorders, though causality is not established. [11]

---

4. Clinical Presentation

Motor Tics

Motor tics are classified as simple or complex:

Simple Motor Tics (brief, involving single muscle group):

• Eye blinking (often the first tic to appear)
• Facial grimacing
• Nose twitching
• Shoulder shrugging
• Head jerking or nodding
• Jaw movements

Complex Motor Tics (longer duration, involve multiple muscle groups or appear purposeful):

• Jumping or hopping
• Touching objects or people
• Smelling objects
• Twirling or spinning
• Echopraxia: Imitating movements of others
• Copropraxia: Obscene gestures (rare, less than 5%)
• Self-injurious tics: Hitting oneself, biting lip, banging head

Vocal (Phonic) Tics

Vocal tics result from air movement through the nose, mouth, or throat.

Simple Vocal Tics:

• Throat clearing (very common)
• Sniffing
• Grunting
• Coughing
• Hissing or squeaking sounds
• Barking

Complex Vocal Tics:

• Syllables, words, or phrases
• Palilalia: Repeating one's own words
• Echolalia: Repeating words of others
• Coprolalia: Involuntary utterance of obscene or socially inappropriate words (~10% of cases)

Premonitory Urge

Approximately 90% of adolescents and adults with Tourette's report a premonitory urge—an uncomfortable, often localised sensation (itch, tension, pressure, "not-just-right" feeling) that builds before a tic. Performing the tic provides temporary relief. This feature is critical for distinguishing tics from other involuntary movements (chorea, myoclonus, dystonia), which lack this volitional quality. [17]

Younger children (under age 10) often cannot articulate the premonitory urge, which develops with age and cognitive maturity.

Suppressibility

Unlike seizures or chorea, tics are suppressible. Patients can voluntarily suppress tics for seconds to minutes, though this requires significant effort and is often followed by a "rebound" of tics when concentration is relaxed. This suppressibility can lead to underestimation of tic severity during medical consultations, with parents reporting that tics are much worse at home after "holding them in" all day at school.

Waxing and Waning Course

Tic severity fluctuates over time:

• Individual tics may disappear and be replaced by new ones.
• Tics worsen with stress, excitement, fatigue, illness, or anxiety.
• Tics may diminish during focused activities (playing video games, reading).
• Seasonal variation is common.
• Puberty often marks the peak of tic severity.

Temporal Pattern and Natural History

---

5. Differential Diagnosis

Accurate diagnosis requires exclusion of alternative causes of tics or tic-like movements.

Red Flag Features Suggesting Alternative Diagnosis:

• Onset after age 18 (consider Huntington's, drug-induced, structural lesion)
• Rapidly progressive course
• Associated neurological signs (ataxia, seizures, cognitive decline)
• Absence of waxing and waning pattern
• Fixed, sustained postures (dystonia)

---

6. Clinical Examination

Observation

• Watch the patient during history-taking: Tics may be suppressed during formal examination but visible during casual conversation with parents.
• Note tic characteristics: Frequency, intensity, distribution, complexity.
• Assess functional impact: Does the patient have injuries from tics? Social embarrassment?

Neurological Examination

The neurological examination in isolated Tourette's Syndrome should be entirely normal. Any abnormalities suggest an alternative or additional diagnosis.

Look for:

• Wilson's Disease: Kayser-Fleischer rings (slit-lamp examination), hepatomegaly, bradykinesia, dystonia
• Huntington's Disease: Chorea, saccadic eye movement abnormalities, cognitive impairment
• Sydenham's Chorea: "Milkmaid grip" (irregular hand squeezing), "darting tongue," chorea
• Structural lesions: Focal neurological signs, papilloedema

Psychiatric Assessment

Given high comorbidity rates, comprehensive assessment must include:

• ADHD symptoms: Inattention, hyperactivity, impulsivity
• OCD symptoms: Obsessions and compulsions (often symmetry/ordering in TS)
• Anxiety and mood: Generalised anxiety, social anxiety, depression
• Sleep disturbance: Insomnia, parasomnias
• Behavioural problems: Aggression, oppositional behaviour
• Learning difficulties: Academic performance, reading/writing problems

Tic Severity Scales

Standardised scales help quantify tic severity:

• Yale Global Tic Severity Scale (YGTSS): Gold standard; rates motor and vocal tics separately on number, frequency, intensity, complexity, and interference.
• Premonitory Urge for Tics Scale (PUTS): Assesses urge severity.

---

7. Investigations

Diagnosis

Tourette's Syndrome is a clinical diagnosis based on history and examination. There is no confirmatory laboratory test, imaging study, or biomarker.

DSM-5 Diagnostic Criteria for Tourette's Disorder: [18]

1. Both multiple motor tics AND one or more vocal tics have been present at some time, although not necessarily concurrently.
2. Tics occur many times a day, nearly every day, or intermittently for more than one year. During this period, there was never a tic-free period of more than 3 consecutive months.
3. Onset before age 18 years.
4. Disturbance is not attributable to the physiological effects of a substance (e.g., cocaine) or another medical condition (e.g., Huntington's disease, post-viral encephalitis).

When to Investigate

In typical presentations (childhood onset, waxing/waning, comorbid ADHD/OCD, normal examination), no investigations are needed. Investigations are indicated in atypical cases:

---

8. Management

Management of Tourette's Syndrome is individualised and depends on tic severity, functional impairment, and presence of comorbidities. In many cases, psychoeducation and watchful waiting are sufficient. [19,20]

Management Algorithm

         DIAGNOSIS OF TOURETTE'S SYNDROME
    (Motor + Vocal Tics >1 year, Onset less than 18 years)
                    ↓
              ASSESS SEVERITY
       (Yale Global Tic Severity Scale)
   (Screen for ADHD, OCD, Anxiety, Depression)
                    ↓
        ┌───────────┴───────────────┐
     MILD TICS                 MODERATE-SEVERE TICS
  (Not distressing)             (Functional impairment,
   (No impairment)               pain, social stigma)
        ↓                              ↓
  PSYCHOEDUCATION              PSYCHOEDUCATION +
  Reassure patient/family       BEHAVIOURAL THERAPY
  Educate school                (First-line treatment)
  Monitor                       - CBIT (Comprehensive
  Treat comorbidities             Behavioural Intervention
                                  for Tics)
                                - Habit Reversal Training
                                     ↓
                             If inadequate response:
                              PHARMACOTHERAPY
                                (Second-line)
                              - Alpha-2 agonists
                                (Clonidine, Guanfacine)
                              - Antipsychotics
                                (Aripiprazole, Risperidone,
                                 Haloperidol)
                                     ↓
                            If refractory:
                          - Botulinum toxin (focal tics)
                          - Deep brain stimulation (DBS)
                            (severe, disabling cases)

        THROUGHOUT: Address comorbidities
           (ADHD, OCD, Anxiety, Sleep)

1. Psychoeducation (Essential in All Cases)

Patient and Family Education:

• Explain that TS is a neurodevelopmental disorder, not a behavioural problem or "bad habit."
• Tics are involuntary; punishment is inappropriate and harmful.
• Tics typically peak in early adolescence and improve in late teens.
• Comorbidities (ADHD, OCD) often cause more impairment than tics.
• Stress exacerbates tics; relaxation and support help.

School Liaison:

• Educate teachers about TS.
• Implement accommodations: extra time for exams, breaks if needed, ignore tics, prevent bullying.
• Avoid drawing attention to tics, which can worsen them.

Prognosis Counselling:

• "Rule of thirds": 1/3 become tic-free, 1/3 markedly improve, 1/3 have persistent tics.
• Coprolalia occurs in less than 10% (dispel media stereotypes).

2. Behavioural Therapy (First-Line for Moderate-Severe Tics)

Comprehensive Behavioural Intervention for Tics (CBIT) is the first-line treatment for tics causing functional impairment. [3,19]

CBIT Components:

1. Psychoeducation: Understanding tics and triggers.
2. Habit Reversal Training (HRT):
   • Awareness training: Identifying premonitory urges.
   • Competing response: Performing a physically incompatible response (e.g., tensing antagonist muscles) when urge arises.
   • Social support: Reinforcement from family.
3. Function-based interventions: Modifying environmental triggers.
4. Relaxation training: Reducing stress and anxiety.

Evidence: A landmark RCT by Piacentini et al. (2010) demonstrated that CBIT significantly reduced tic severity compared to supportive therapy, with benefits sustained at 6 months. [3] European and American guidelines now recommend behavioural therapy as first-line before pharmacotherapy.

Exposure and Response Prevention (ERP) for premonitory urges is another emerging approach, showing promise in reducing urge intensity and tic frequency.

3. Pharmacotherapy (Second-Line)

Medications are reserved for patients with:

• Moderate to severe tics impairing function or causing pain/injury
• Inadequate response to behavioural therapy
• Patient/family preference

No medication is curative; all aim to reduce tic frequency and intensity.

Alpha-2 Adrenergic Agonists (First-Line Pharmacotherapy)

Mechanism: Modulate noradrenergic neurotransmission; indirect effects on dopamine.

Evidence: Moderate tic reduction (20-30%). Particularly useful when ADHD is comorbid. [19]

Antipsychotics (Dopamine Antagonists)

Mechanism: Block dopamine D2 receptors in the striatum.

Evidence: Aripiprazole is increasingly preferred due to better tolerability. Risperidone and haloperidol have strong efficacy but higher side effect burden. [19,20]

Monitoring:

• Baseline: Weight, BMI, glucose, lipids, prolactin, ECG (for pimozide)
• Follow-up: Weight and metabolic parameters every 3 months
• Screen for extrapyramidal symptoms (EPS) and tardive dyskinesia (AIMS scale)

VMAT2 Inhibitors

Deutetrabenazine and valbenazine (VMAT2 inhibitors) deplete dopamine. Emerging evidence supports use in TS, though not yet widely available in all countries.

Other Medications

• Topiramate: Modest tic reduction; may also help comorbid impulse control issues.
• Baclofen: Limited evidence.
• Clonazepam: May help tics and anxiety but risk of dependence.
• Cannabis-based therapies: Emerging interest; insufficient evidence currently.

4. Botulinum Toxin Injections

Indication: Focal, bothersome motor or vocal tics (e.g., severe neck tics causing pain or cervical radiculopathy).

Mechanism: Temporary muscle paralysis.

Evidence: Small studies show benefit for selected patients; effects last 3-4 months; requires repeated injections. [20]

5. Deep Brain Stimulation (DBS)

Indication: Severe, refractory Tourette's Syndrome causing significant disability despite optimal medical and behavioural therapy.

Target sites: Centromedian-parafascicular complex of thalamus, globus pallidus internus (GPi), anterior limb of internal capsule.

Evidence: Case series and small trials show 30-50% tic reduction. Still considered experimental; reserved for adults with intractable tics. [20]

Risks: Infection, haemorrhage, hardware complications, limited long-term data.

6. Management of Comorbidities

Often more important than treating the tics themselves.

Note on Stimulants: Historically, stimulants were thought to precipitate or worsen tics, and TS was considered a contraindication. Current evidence suggests that in therapeutic doses, stimulants are generally safe and effective for ADHD in patients with TS, with minimal impact on tic severity. [19]

---

9. Complications

Physical Complications

• Musculoskeletal pain: Chronic neck, back, or shoulder pain from repetitive motor tics
• Cervical radiculopathy or myelopathy: From severe neck-jerking tics
• Self-injury: Biting lips/tongue, hitting oneself, eye injury from blinking tics
• Dental/orthodontic problems: From jaw tics
• Fatigue: From chronic muscle tension and tic suppression

Psychosocial Complications

• Bullying and social isolation: Particularly in school-aged children
• Low self-esteem: Shame and embarrassment about tics
• Academic underachievement: Due to tics, ADHD, or school avoidance
• Employment difficulties: In adulthood, tics may interfere with work
• Family stress: Impact on family dynamics and parental mental health

Psychiatric Complications

• Depression and anxiety: Secondary to social stigma and chronic stress
• Suicidal ideation: In severe cases with comorbid depression
• Substance misuse: Self-medication for tics or comorbid conditions
• Functional impairment: Reduced quality of life

---

10. Prognosis and Outcomes

Natural History

Tourette's Syndrome typically follows a characteristic trajectory:

• Childhood (4-6 years): Onset of simple motor tics
• Late childhood (7-9 years): Emergence of vocal tics; diagnosis usually made
• Early adolescence (10-12 years): Peak tic severity
• Late adolescence (16-18 years): Gradual improvement in most cases
• Adulthood: Variable outcomes

Long-Term Outcomes ("Rule of Thirds")

By early adulthood: [9]

• ~30% become tic-free (complete remission)
• ~40% have markedly improved tics (mild, not impairing)
• ~30% have persistent moderate-severe tics

Predictors of Persistence

Factors associated with worse prognosis (tics persisting into adulthood):

• Severe tics in childhood
• Presence of coprolalia or self-injurious tics
• Comorbid OCD (tics + OCD tend to persist longer)
• Family history of chronic tics
• Later age at tic onset (paradoxically)

Functional Outcomes

• Most individuals with TS lead normal, productive lives.
• Educational attainment, employment, and relationships are often unaffected or minimally affected, especially with appropriate support and treatment of comorbidities.
• Quality of life is strongly influenced by comorbidities (ADHD, OCD, anxiety) rather than tic severity alone.

Mortality

Tourette's Syndrome does not reduce life expectancy. However, severe comorbid psychiatric conditions (e.g., major depression) may increase suicide risk, underscoring the importance of comprehensive mental health care.

---

11. Prevention and Screening

Primary Prevention

No established primary prevention strategies exist, as the aetiology is largely genetic and not fully understood. Hypothetical strategies include:

• Optimising maternal health during pregnancy (avoiding smoking, managing stress)
• Prompt treatment of Streptococcal infections (for PANDAS hypothesis, though unproven)

Screening

There is no population-wide screening for Tourette's Syndrome. However, clinicians should:

• Maintain high index of suspicion in children presenting with repetitive movements or vocalisations
• Screen for tics in children with ADHD or OCD
• Screen for comorbid ADHD, OCD, anxiety, and depression in all diagnosed cases

Genetic Counselling

Given the heritable nature of TS, genetic counselling may be offered to families, particularly those with multiple affected members. However, the polygenic nature limits predictive testing.

---

12. Key Guidelines and Evidence

Major Guidelines

Landmark Evidence

1. Piacentini et al. (2010) - CBIT RCT [3]
Randomised controlled trial comparing CBIT to supportive psychotherapy in children and adolescents with TS. CBIT led to significantly greater reduction in tic severity, with benefits maintained at 6-month follow-up. This trial established behavioural therapy as first-line treatment.

2. Pringsheim et al. (2019) - AAN Practice Guideline [19]
Systematic review and evidence-based recommendations for tic treatment. Concluded that CBIT has the strongest evidence for efficacy without side effects, followed by antipsychotics (haloperidol, risperidone, aripiprazole) and alpha-2 agonists.

3. Scharf et al. (2015) - Population Prevalence [6]
Systematic review estimating prevalence of TS at 0.3-0.9% in children, with higher rates in special educational settings.

4. Leckman et al. (1998) - Natural History [9]
Longitudinal study showing that tic severity peaks in early adolescence and declines in most cases by early adulthood.

5. Bloch et al. (2006) - Meta-analysis of Pharmacotherapy [20]
Meta-analysis showing that antipsychotics (especially haloperidol, risperidone, pimozide) and alpha-2 agonists reduce tic severity, though effect sizes are modest and side effects common.

---

13. Exam-Focused Content

Common Exam Questions (MRCPCH, MRCP, Psychiatry MRCPsych)

1. "Define Tourette's Syndrome."
Answer: Tourette's Syndrome is a neurodevelopmental disorder characterised by multiple motor tics and at least one vocal tic, present for more than one year, with onset before age 18 years, not attributable to substances or other medical conditions.

2. "What are the most common comorbidities in Tourette's Syndrome?"
Answer: ADHD (50-60%) and OCD (30-50%) are the most common comorbidities. Anxiety disorders, depression, and learning difficulties are also frequent. These comorbidities often cause greater impairment than the tics themselves.

3. "What is the first-line treatment for moderate to severe tics in Tourette's Syndrome?"
Answer: Comprehensive Behavioural Intervention for Tics (CBIT), which includes habit reversal training. Psychoeducation is essential in all cases. Pharmacotherapy (e.g., alpha-2 agonists, antipsychotics) is second-line.

4. "What is coprolalia, and how common is it?"
Answer: Coprolalia is the involuntary utterance of obscene or socially inappropriate words or phrases. It occurs in fewer than 10% of patients with Tourette's Syndrome and is not required for diagnosis.

5. "What is a premonitory urge?"
Answer: A premonitory urge is an uncomfortable sensation (itch, tension, pressure, "not-just-right" feeling) that precedes a tic. Performing the tic temporarily relieves this urge. It is present in ~90% of adolescents and adults with TS and helps distinguish tics from other involuntary movements.

6. "What is PANDAS?"
Answer: Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections. A controversial entity proposing that a subset of acute-onset tics and OCD result from autoimmune response to Group A Streptococcus. Evidence is mixed; testing for ASOT is reasonable in explosive onset cases.

7. "Can you use stimulants to treat ADHD in a child with Tourette's Syndrome?"
Answer: Yes. Current evidence suggests that therapeutic doses of stimulants (methylphenidate, amphetamines) are generally safe and do not significantly worsen tics in most children. ADHD should be treated if causing impairment. Monitor tics but do not withhold effective ADHD treatment.

Viva Points

Viva Point: Opening Statement:
"Tourette's Syndrome is a childhood-onset neurodevelopmental disorder characterised by multiple motor tics and at least one vocal tic, persisting for more than one year. It affects approximately 1% of school-aged children, with a 3:1 male predominance. The condition is highly heritable and involves dysfunction in cortico-striato-thalamo-cortical circuits, with dopaminergic hyperactivity in the basal ganglia playing a key role."

Key Facts to Mention:

• Diagnostic criteria: Multiple motor + ≥1 vocal tic, >1 year, onset less than 18 years
• Premonitory urge: 90% experience uncomfortable sensation relieved by tic
• Waxing and waning: Tic severity fluctuates; different tics replace each other
• Comorbidities: ADHD 50-60%, OCD 30-50% (often cause more impairment than tics)
• First-line treatment: Psychoeducation for all; CBIT (behavioural therapy) for moderate-severe tics
• Pharmacotherapy: Alpha-2 agonists (clonidine, guanfacine) or antipsychotics (aripiprazole, risperidone) second-line
• Prognosis: "Rule of thirds"—1/3 remit, 1/3 markedly improve, 1/3 persistent tics
• Coprolalia: less than 10% (dispel media myths)

Differential Diagnosis to Mention:

• Primary tic disorders (provisional, chronic motor/vocal)
• Drug-induced (stimulants, antipsychotics)
• Post-infectious (Sydenham's chorea, PANDAS)
• Wilson's disease, Huntington's disease
• Functional tic-like behaviours

Evidence to Cite:

• Piacentini et al. (2010): RCT showing CBIT superior to supportive therapy
• AAN 2019 Guideline: CBIT first-line, pharmacotherapy second-line
• Pringsheim et al. (2019): Evidence-based treatment recommendations

Common Mistakes (What Fails Candidates)

❌ Stating that Tourette's always involves coprolalia (only less than 10% of cases)
❌ Failing to screen for and address comorbidities (ADHD, OCD, anxiety)
❌ Jumping to pharmacotherapy before psychoeducation and behavioural therapy
❌ Describing tics as purely involuntary (they are suppressible, unlike chorea or myoclonus)
❌ Withholding stimulants in ADHD due to TS diagnosis (current evidence supports safe use)
❌ Not recognising red flags (adult onset, progressive course, neurological signs → investigate)
❌ Omitting premonitory urge from clinical description (key distinguishing feature)

Model Answer: Clinical Scenario

Q: A 10-year-old boy presents with a 2-year history of eye blinking, shoulder shrugging, and throat clearing. His mother reports the symptoms wax and wane, worsen when he's anxious, and improve when he's focused on video games. He can suppress them briefly but says it feels uncomfortable. He's struggling academically and is often distracted. How would you approach this case?

Model Answer:

"This history is highly suggestive of Tourette's Syndrome. The presence of multiple motor tics (eye blinking, shoulder shrugging) and a vocal tic (throat clearing) for more than one year, with onset before age 18, meets DSM-5 criteria. The waxing and waning course, exacerbation with stress, and the premonitory urge (uncomfortable feeling) are characteristic features. The suppressibility helps distinguish tics from other involuntary movements such as chorea or myoclonus.

I would take a thorough history to confirm the tic characteristics and timeline, explore the impact on his quality of life, and screen for common comorbidities, particularly ADHD and OCD. His academic struggles and distractibility raise concern for comorbid ADHD, which occurs in 50-60% of children with Tourette's and often causes more functional impairment than the tics themselves.

On examination, I would observe for tics during the consultation, though they may be suppressed. The neurological examination should be normal in isolated Tourette's. I would look for red flags suggesting alternative diagnoses, such as Kayser-Fleischer rings (Wilson's disease), chorea (Sydenham's, Huntington's), or other neurological signs. I would also assess for signs of self-injury from tics.

In a typical case like this, no investigations are needed, as Tourette's is a clinical diagnosis. However, if there were atypical features—such as onset after age 18, rapidly progressive course, or abnormal neurological signs—I would consider MRI brain, copper studies, or other relevant tests.

Management would begin with psychoeducation for the patient and family, explaining that Tourette's is a neurodevelopmental disorder, not a behavioural problem. I would reassure them that tics typically peak in early adolescence and improve in late teens, and that many individuals lead normal, productive lives. I would liaise with his school to implement accommodations and prevent bullying.

For the tics, if they are causing significant distress or functional impairment, I would recommend Comprehensive Behavioural Intervention for Tics (CBIT) as first-line treatment, based on evidence from the Piacentini et al. RCT and current AAN guidelines. CBIT includes habit reversal training, where the child learns to recognise the premonitory urge and perform a competing response.

If the tics remain impairing despite behavioural therapy, I would consider pharmacotherapy. Alpha-2 agonists such as guanfacine or clonidine are first-line medications and would be particularly appropriate given his possible comorbid ADHD. If tics are more severe, an antipsychotic such as aripiprazole could be considered, with careful monitoring for side effects including weight gain and extrapyramidal symptoms.

Critically, I would address the comorbid ADHD if confirmed, as this is likely contributing significantly to his academic struggles. Current evidence supports the safe use of stimulants in children with Tourette's; they do not typically worsen tics and should not be withheld if ADHD is impairing function. Alternatively, atomoxetine or guanfacine could address both ADHD and tics.

I would arrange follow-up to monitor tic severity, treatment response, academic progress, and mental health, with referral to paediatric neurology or psychiatry if needed."

---

14. Patient and Layperson Explanation

What is Tourette's Syndrome?

Tourette's Syndrome is a condition that causes sudden, repeated movements or sounds called tics. Tics are not on purpose, but they're also not completely involuntary—people with Tourette's can hold them in for a little while, like trying to hold in a sneeze. Eventually, the tic has to come out, and holding it in can feel uncomfortable.

What causes it?

Tourette's runs in families, which means it's partly genetic. It's caused by differences in how certain parts of the brain (especially the areas that control movement) work. The brain sends extra signals to the muscles, causing tics.

What are tics like?

Tics can be movements (like blinking, shrugging shoulders, or jerking your head) or sounds (like throat clearing, sniffing, or grunting). Some people with Tourette's have simple tics (quick and simple movements), while others have complex tics (longer movements that might look purposeful).

Do people with Tourette's always swear?

No! This is a common myth. Only about 1 in 10 people with Tourette's have coprolalia (involuntary swearing). Most people with Tourette's just have simple tics like blinking or throat clearing.

Will it go away?

For most people, tics are worst in the early teenage years and get much better in late teens and adulthood. About 1 in 3 people become tic-free as adults, another third have much milder tics, and the remaining third still have noticeable tics. Even when tics continue, most people live normal, happy, successful lives.

Is it dangerous?

Tourette's itself is not dangerous or life-threatening. The main challenges are dealing with embarrassment, being teased, or having difficulty concentrating at school. Some people with Tourette's also have ADHD or OCD, which can be more challenging than the tics themselves.

How is it treated?

Education and support are the most important treatments. Many people with mild tics don't need medication at all. For those who are bothered by their tics, behavioural therapy (learning techniques to manage tics) is the first-line treatment. Medications are available if needed, but they don't cure Tourette's—they just reduce tic frequency and severity.

What can I do to help someone with Tourette's?

• Don't make a big deal out of tics. The person can't control them, and pointing them out makes it worse.
• Don't tell them to stop. They're already trying!
• Educate others to prevent bullying and teasing.
• Be supportive and understanding. Living with Tourette's can be exhausting and stressful.

---

15. References

1. Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4):173-196. doi:10.1007/s00787-011-0163-7

2. Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res. 2008;65(5):461-472. doi:10.1016/j.jpsychores.2008.03.006

3. Piacentini J, Woods DW, Scahill L, et al. Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA. 2010;303(19):1929-1937. doi:10.1001/jama.2010.607

4. Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol. 2000;42(7):436-447. doi:10.1017/s0012162200000839

5. Hirschtritt ME, Lee PC, Pauls DL, et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015;72(4):325-333. doi:10.1001/jamapsychiatry.2014.2650

6. Scharf JM, Miller LL, Gauvin CA, Alabiso J, Mathews CA, Ben-Shlomo Y. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30(2):221-228. doi:10.1002/mds.26089

7. Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol. 2012;47(2):77-90. doi:10.1016/j.pediatrneurol.2012.05.002

8. Martino D, Ganos C, Pringsheim TM. Tourette syndrome and chronic tic disorders: the clinical spectrum beyond tics. Int Rev Neurobiol. 2017;134:1461-1490. doi:10.1016/bs.irn.2017.05.006

9. Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics. 1998;102(1 Pt 1):14-19. doi:10.1542/peds.102.1.14

10. Davis LK, Yu D, Keenan CL, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;9(10):e1003864. doi:10.1371/journal.pgen.1003864

11. Browne HA, Hansen SN, Buxbaum JD, et al. Prenatal maternal smoking and increased risk for Tourette syndrome and chronic tic disorders. J Am Acad Child Adolesc Psychiatry. 2016;55(9):784-791. doi:10.1016/j.jaac.2016.06.010

12. Swedo SE, Leckman JF, Rose NR. From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (pediatric acute-onset neuropsychiatric syndrome). Pediatr Therapeut. 2012;2(2):113. doi:10.4172/2161-0665.1000113

13. Willsey AJ, Fernandez TV, Yu D, et al. De novo coding variants are strongly associated with Tourette disorder. Neuron. 2017;94(3):486-499.e9. doi:10.1016/j.neuron.2017.04.024

14. Singer HS, Szymanski S, Giuliano J, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry. 2002;159(8):1329-1336. doi:10.1176/appi.ajp.159.8.1329

15. Müller-Vahl KR, Grosskreutz J, Prell T, et al. Tics are caused by alterations in prefrontal areas, thalamus and putamen, while changes in the cingulate gyrus reflect secondary compensatory mechanisms. BMC Neurosci. 2014;15:6. doi:10.1186/1471-2202-15-6

16. Greene DJ, Williams AC 3rd, Koller JM, Schlaggar BL, Black KJ. Brain structure in pediatric Tourette syndrome. Mol Psychiatry. 2017;22(7):972-980. doi:10.1038/mp.2016.194

17. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. Am J Psychiatry. 1993;150(1):98-102. doi:10.1176/ajp.150.1.98

18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing; 2013.

19. Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):896-906. doi:10.1212/WNL.0000000000007466

20. Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry. 2022;31(3):425-441. doi:10.1007/s00787-021-01899-z

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for patient management.